Showing results (21-30 of 44) with videos related to
Sort By:
Pageof 5
Oncogene|July 5, 2018
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancerKristina Golfmann, Lydia Meder, Mirjam Koker, et al.European Journal of Haematology|September 3, 2022
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)Sarah Gillessen, Annette Pluetschow, Vladan Vucinic, et al.Blood|February 3, 2016
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trialsBoris Böll, Helen Goergen, Karolin Behringer, et al.Hemasphere|June 5, 2024
Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphomaBerit Müller-Meinhard, Nicole Seifert, Johanna Grund, et al.British Journal of Haematology|September 14, 2021
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trialElena Gerhard-Hartmann, Helen Goergen, Paul J Bröckelmann, et al.Leukemia|September 29, 2021
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphomaMaria A Garcia-Marquez, Martin Thelen, Sarah Reinke, et al.European Journal of Haematology|February 19, 2024
Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCRJan-Michel Heger, Yannick d'Hargues, Fanni Kleinert, et al.International Journal of Cancer|November 19, 2013
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinomaAchim Rothe, Ron D Jachimowicz, Sven Borchmann, et al.British Journal of Haematology|November 14, 2021
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic, et al.Journal for Immunotherapy of Cancer|October 12, 2022
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumorsSven Borchmann, Carolin Selenz, Mia Lohmann, et al.Pageof 5